Portfolio of Genetic Testing Stocks
Here are 8 genetic testing stocks.
|8 Genetic Testing Stocks|
Stock Returns & Price Chart
Recent Prices &
|Genetic Technologies Ltd||GENE|
|HTG Molecular Diagnostics†||HTGM|
|Price data from Quandl as of most recent close.|
To inspect the performance of the Genetic Testing Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.The 3 stocks included in the portfolio computations are: GHDX, EXAS and GENE. The current value of the portfolio assumes that $3,333.33 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. The 5 stocks excluded from the portfolio computations because of insufficient price data are: CGIX, HTGM, NVTA, NTRA and VCYT.
The current value of a $10,000 investment is $139,127. The percent return is 1,291.27%. The annualized return is 30.12%.
|Return Summary for Genetic Testing Stocks|
|Current Value of Investment||$139,127.28|
|Number Profitable Returns||5,904|
|Percent Profitable Returns||81.32%|
|Number Unprofitable Returns||1,356|
|Percent Unprofitable Returns||18.68%|
|Profitable to Unprofitable Returns Ratio||4.35|
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.